Latest Comments

The anti-vaccination movement and public health

The anti-vaccination movement and public health

Brexit: new alliance hopes to ensure healthcare stability in an uncertain future

Brexit: new alliance hopes to ensure healthcare stability in an uncertain future

Niche is the new normal: the growth of the orphan drugs market

Niche is the new normal: the growth of the orphan drugs market

NeuPSIG 2017: personalized treatments may hold the key to treatment progress in neuropathic pain

NeuPSIG 2017: personalized treatments may hold the key to treatment progress in neuropathic pain

NeuPSIG 2017: cell therapies may hold the key to opioid use in neuropathic pain

NeuPSIG 2017: cell therapies may hold the key to opioid use in neuropathic pain

EULAR 2017: Big pharma dives back into the lupus pipeline

EULAR 2017: Big pharma dives back into the lupus pipeline

EULAR 2017: Osteoarthritis pipeline product shows promise

EULAR 2017: Osteoarthritis pipeline product shows promise

DEVOTE trial update: ultra long-acting Insulin Tresiba as safe as insulin glargine

DEVOTE trial update: ultra long-acting Insulin Tresiba as safe as insulin glargine

Chemo-free triplet regimens on the horizon for CLL

Chemo-free triplet regimens on the horizon for CLL

Practice changing results at the ASCO conference: Lynparza is poised to modify the treatment paradigm of metastatic breast cancer

Practice changing results at the ASCO conference: Lynparza is poised to modify the treatment paradigm of metastatic breast cancer

Poor tolerability of Opdivo + Yervoy in frontline NSCLC could be Achilles heel

Poor tolerability of Opdivo + Yervoy in frontline NSCLC could be Achilles heel

Increased risk of amputation if taking type 2 diabetes drug Invokana

Increased risk of amputation if taking type 2 diabetes drug Invokana

New drug class set to reduce migraine misery

New drug class set to reduce migraine misery

HIV and malaria: case studies in combatting drug resistance through improved adherence

HIV and malaria: case studies in combatting drug resistance through improved adherence

Pipeline biosimilar surge in emerging markets

Pipeline biosimilar surge in emerging markets

Can DAA treatment increase the risk of HCC? Emerging data points towards ‘no’

Can DAA treatment increase the risk of HCC? Emerging data points towards ‘no’

Highlights from the 2017 ATS Conference: positive results for AstraZeneca’s Daliresp beyond reducing the risk of exacerbations

Highlights from the 2017 ATS Conference: positive results for AstraZeneca’s Daliresp beyond reducing the risk of exacerbations

Eiger Bio’s PAH drug Ubenimex moves one step closer to fulfilling an unmet need

Eiger Bio’s PAH drug Ubenimex moves one step closer to fulfilling an unmet need

Seikagaku inks deal with Ono Pharmaceutical, strengthening its position in the Osteoarthritis market

Seikagaku inks deal with Ono Pharmaceutical, strengthening its position in the Osteoarthritis market

Pacific Biosciences: don’t count them out yet

Pacific Biosciences: don’t count them out yet

Gilead and AbbVie look to fill remaining gaps in Hepatitis C treatment

Gilead and AbbVie look to fill remaining gaps in Hepatitis C treatment